Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe

Noriko Matsunaga, Taeko Nishijima, Kenji Hattori, Hisashi Iizasa, Keiko Yamamoto, Junko Kizu, Akira Takanaka, Akinobu Morikawa, Emi Nakashima

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Previous reports have shown that the determination of drug metabolism capacity can be made by the pharmacokinetic estimation of the quantity of cytochrome P450 (CYP) in vivo (PKCYP-test), in which an apparent liver-to-blood free concentration gradient in vivo (qg) is introduced, which is useful for evaluating fluctuations of CYP1A2 in rats. The aim of the present study was to examine the application of the PKCYP-test to evaluate the quantity of in vivo CYP2C11 by using tolbutamide as a probe, to confirm its validity using a physiologically-based pharmacokinetic rat model. Rats treated with carbon tetrachloride (CCl4-treated rats) were used as a model for low levels of CYP2C11 in the liver. In CCl4-treated rats, the total body clearance (CLtot) of tolbutamide and the amount of CYP2C11 fell to about a quarter and a third of that in control rats, respectively. The time-course of tolbutamide concentrations in serum in control rats could be simulated by a physiologically-based pharmacokinetic model. In CCl4-treated rats, take into consideration the qg value of control rats, the level of CYP2C11 was accurately predicted by the PKCYP-test, and the time-course of tolbutamide concentrations in serum could be predicted by the same physiologically-based pharmacokinetic model. In conclusion, we have shown that the PKCYP-test can be used to predict levels of CYP2C11. It was also demonstrated that the qg and amount of CYP are useful parameters in the PKCYP-test by constructing a physiologically-based pharmacokinetic model which was applied to the PKCYP-test.

Original languageEnglish
Pages (from-to)1305-1310
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume24
Issue number11
DOIs
Publication statusPublished - 2001

Fingerprint

Tolbutamide
Pharmacokinetics
Cytochrome P-450 Enzyme System
Cytochrome P-450 CYP1A2
Carbon Tetrachloride
Liver
Serum

Keywords

  • Carbon tetrachloride-treated
  • CYP2C11
  • Physiologically-based pharmacokinetic model
  • PKCYP-test
  • Probe

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Matsunaga, N., Nishijima, T., Hattori, K., Iizasa, H., Yamamoto, K., Kizu, J., ... Nakashima, E. (2001). Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe. Biological and Pharmaceutical Bulletin, 24(11), 1305-1310. https://doi.org/10.1248/bpb.24.1305

Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe. / Matsunaga, Noriko; Nishijima, Taeko; Hattori, Kenji; Iizasa, Hisashi; Yamamoto, Keiko; Kizu, Junko; Takanaka, Akira; Morikawa, Akinobu; Nakashima, Emi.

In: Biological and Pharmaceutical Bulletin, Vol. 24, No. 11, 2001, p. 1305-1310.

Research output: Contribution to journalArticle

Matsunaga, N, Nishijima, T, Hattori, K, Iizasa, H, Yamamoto, K, Kizu, J, Takanaka, A, Morikawa, A & Nakashima, E 2001, 'Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe', Biological and Pharmaceutical Bulletin, vol. 24, no. 11, pp. 1305-1310. https://doi.org/10.1248/bpb.24.1305
Matsunaga, Noriko ; Nishijima, Taeko ; Hattori, Kenji ; Iizasa, Hisashi ; Yamamoto, Keiko ; Kizu, Junko ; Takanaka, Akira ; Morikawa, Akinobu ; Nakashima, Emi. / Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe. In: Biological and Pharmaceutical Bulletin. 2001 ; Vol. 24, No. 11. pp. 1305-1310.
@article{b37d40249d374b01965a32d13632f974,
title = "Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe",
abstract = "Previous reports have shown that the determination of drug metabolism capacity can be made by the pharmacokinetic estimation of the quantity of cytochrome P450 (CYP) in vivo (PKCYP-test), in which an apparent liver-to-blood free concentration gradient in vivo (qg) is introduced, which is useful for evaluating fluctuations of CYP1A2 in rats. The aim of the present study was to examine the application of the PKCYP-test to evaluate the quantity of in vivo CYP2C11 by using tolbutamide as a probe, to confirm its validity using a physiologically-based pharmacokinetic rat model. Rats treated with carbon tetrachloride (CCl4-treated rats) were used as a model for low levels of CYP2C11 in the liver. In CCl4-treated rats, the total body clearance (CLtot) of tolbutamide and the amount of CYP2C11 fell to about a quarter and a third of that in control rats, respectively. The time-course of tolbutamide concentrations in serum in control rats could be simulated by a physiologically-based pharmacokinetic model. In CCl4-treated rats, take into consideration the qg value of control rats, the level of CYP2C11 was accurately predicted by the PKCYP-test, and the time-course of tolbutamide concentrations in serum could be predicted by the same physiologically-based pharmacokinetic model. In conclusion, we have shown that the PKCYP-test can be used to predict levels of CYP2C11. It was also demonstrated that the qg and amount of CYP are useful parameters in the PKCYP-test by constructing a physiologically-based pharmacokinetic model which was applied to the PKCYP-test.",
keywords = "Carbon tetrachloride-treated, CYP2C11, Physiologically-based pharmacokinetic model, PKCYP-test, Probe",
author = "Noriko Matsunaga and Taeko Nishijima and Kenji Hattori and Hisashi Iizasa and Keiko Yamamoto and Junko Kizu and Akira Takanaka and Akinobu Morikawa and Emi Nakashima",
year = "2001",
doi = "10.1248/bpb.24.1305",
language = "English",
volume = "24",
pages = "1305--1310",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe

AU - Matsunaga, Noriko

AU - Nishijima, Taeko

AU - Hattori, Kenji

AU - Iizasa, Hisashi

AU - Yamamoto, Keiko

AU - Kizu, Junko

AU - Takanaka, Akira

AU - Morikawa, Akinobu

AU - Nakashima, Emi

PY - 2001

Y1 - 2001

N2 - Previous reports have shown that the determination of drug metabolism capacity can be made by the pharmacokinetic estimation of the quantity of cytochrome P450 (CYP) in vivo (PKCYP-test), in which an apparent liver-to-blood free concentration gradient in vivo (qg) is introduced, which is useful for evaluating fluctuations of CYP1A2 in rats. The aim of the present study was to examine the application of the PKCYP-test to evaluate the quantity of in vivo CYP2C11 by using tolbutamide as a probe, to confirm its validity using a physiologically-based pharmacokinetic rat model. Rats treated with carbon tetrachloride (CCl4-treated rats) were used as a model for low levels of CYP2C11 in the liver. In CCl4-treated rats, the total body clearance (CLtot) of tolbutamide and the amount of CYP2C11 fell to about a quarter and a third of that in control rats, respectively. The time-course of tolbutamide concentrations in serum in control rats could be simulated by a physiologically-based pharmacokinetic model. In CCl4-treated rats, take into consideration the qg value of control rats, the level of CYP2C11 was accurately predicted by the PKCYP-test, and the time-course of tolbutamide concentrations in serum could be predicted by the same physiologically-based pharmacokinetic model. In conclusion, we have shown that the PKCYP-test can be used to predict levels of CYP2C11. It was also demonstrated that the qg and amount of CYP are useful parameters in the PKCYP-test by constructing a physiologically-based pharmacokinetic model which was applied to the PKCYP-test.

AB - Previous reports have shown that the determination of drug metabolism capacity can be made by the pharmacokinetic estimation of the quantity of cytochrome P450 (CYP) in vivo (PKCYP-test), in which an apparent liver-to-blood free concentration gradient in vivo (qg) is introduced, which is useful for evaluating fluctuations of CYP1A2 in rats. The aim of the present study was to examine the application of the PKCYP-test to evaluate the quantity of in vivo CYP2C11 by using tolbutamide as a probe, to confirm its validity using a physiologically-based pharmacokinetic rat model. Rats treated with carbon tetrachloride (CCl4-treated rats) were used as a model for low levels of CYP2C11 in the liver. In CCl4-treated rats, the total body clearance (CLtot) of tolbutamide and the amount of CYP2C11 fell to about a quarter and a third of that in control rats, respectively. The time-course of tolbutamide concentrations in serum in control rats could be simulated by a physiologically-based pharmacokinetic model. In CCl4-treated rats, take into consideration the qg value of control rats, the level of CYP2C11 was accurately predicted by the PKCYP-test, and the time-course of tolbutamide concentrations in serum could be predicted by the same physiologically-based pharmacokinetic model. In conclusion, we have shown that the PKCYP-test can be used to predict levels of CYP2C11. It was also demonstrated that the qg and amount of CYP are useful parameters in the PKCYP-test by constructing a physiologically-based pharmacokinetic model which was applied to the PKCYP-test.

KW - Carbon tetrachloride-treated

KW - CYP2C11

KW - Physiologically-based pharmacokinetic model

KW - PKCYP-test

KW - Probe

UR - http://www.scopus.com/inward/record.url?scp=0035166830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035166830&partnerID=8YFLogxK

U2 - 10.1248/bpb.24.1305

DO - 10.1248/bpb.24.1305

M3 - Article

C2 - 11725969

AN - SCOPUS:0035166830

VL - 24

SP - 1305

EP - 1310

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 11

ER -